Drug Patents owned by Takeda Pharms Usa

1. Drug name - ACTOPLUS MET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101660 TAKEDA PHARMS USA Solid preparation Jan, 2027

(4 years from now)

US9320714 TAKEDA PHARMS USA Tablet Feb, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
500MG;EQ 15MG BASE TABLET;ORAL Prescription
850MG;EQ 15MG BASE TABLET;ORAL Prescription

2. Drug name - ACTOPLUS MET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470368 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Sep, 2023

(11 months from now)

US9060941 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Sep, 2023

(11 months from now)

US8668931 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Sep, 2023

(11 months from now)

US7959946 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Jul, 2026

(3 years from now)

US7785627 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Jul, 2026

(3 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 15MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
1GM;EQ 30MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

3. Drug name - ALUNBRIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012462 TAKEDA PHARMS USA Phosphorous derivatives as kinase inhibitors
Jul, 2030

(7 years from now)

US10385078 TAKEDA PHARMS USA Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Nov, 2035

(13 years from now)

CN102105150A TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

CN102105150B TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

CN107108559B TAKEDA PHARMS USA 5 - -N4-(2 -) (Dimethyl Phosphoryl) Phenyl] -N2-(2 - -4-(4 - (4 --- Yl)--- Piperazin - -1 - Piperidin - -1 - Yl] - Phenyl) - Pyrimidine - -2, 4 - - Diamine Crystalline Form
Oct, 2035

(13 years from now)

CN107108559A TAKEDA PHARMS USA 5 - -N4-(2 - (- Dimethyl) Phenyl] -N2-(2-Methoxy - -4-[4 - (4-Methylpiperazine - -1 - Yl)--1 - Group]--2, 4-Diamine In Crystalline Form
Oct, 2035

(13 years from now)

EP2300013A1 TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

EP2300013A4 TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

EP2300013B1 TAKEDA PHARMS USA Phosphorous Derivatives As Kinase Inhibitors
May, 2029

(6 years from now)

EP3209647B1 TAKEDA PHARMS USA Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine
Oct, 2035

(13 years from now)

EP3209647A1 TAKEDA PHARMS USA Crystalline Forms Of 5-Chloro-N4-[-2-(Dimethylphosphoryl) Phenyl]-N2-{2-Methoxy-4-[4-(4-Methylpiperazin-1-Yl) Piperidin-1-Yl]Pyrimidine-2,4-Diamine
Oct, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9273077 TAKEDA PHARMS USA Phosphorus derivatives as kinase inhibitors May, 2029

(6 years from now)

US9611283 TAKEDA PHARMS USA Methods for inhibiting cell proliferation in ALK-driven cancers Apr, 2034

(11 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription
180MG TABLET;ORAL Prescription

4. Drug name - COLCRYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7964647 TAKEDA PHARMS USA Colchicine compositions and methods Oct, 2028

(6 years from now)

US8093297 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Oct, 2028

(6 years from now)

US8097655 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Oct, 2028

(6 years from now)

US7964648 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Oct, 2028

(6 years from now)

US7981938 TAKEDA PHARMS USA Colchicine compositions and methods Oct, 2028

(6 years from now)

US8415396 TAKEDA PHARMS USA Colchine compositions and methods Oct, 2028

(6 years from now)

US8415395 TAKEDA PHARMS USA Colchicine compositions and methods Oct, 2028

(6 years from now)

US8093298 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Oct, 2028

(6 years from now)

US8093296 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Oct, 2028

(6 years from now)

US7619004 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Dec, 2028

(6 years from now)

US7935731 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics Dec, 2028

(6 years from now)

US7601758 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares Feb, 2029

(6 years from now)

US7906519 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

US8440722 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

US8440721 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

US7915269 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

US7820681 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent Feb, 2029

(6 years from now)

Drugs and Companies using COLCHICINE ingredient

Treatment: Method of treating gout flares; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; Method of using colchicine for the prophylaxis of gout flares; A method for treatment of gout flares during prophylaxis; Method of administering colchicine to familial mediterranean fever patients

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.6MG TABLET;ORAL Prescription

5. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(3 months from now)

CN1150186C TAKEDA PHARMS USA Benzimidazole Compound Crystal
Jun, 2020

(2 years ago)

CN1355798A TAKEDA PHARMS USA Benzimidazole Compound Crystal
Jun, 2020

(2 years ago)

EP1977751A1 TAKEDA PHARMS USA Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent
Jun, 2020

(2 years ago)

EP1977751B1 TAKEDA PHARMS USA Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent
Jun, 2020

(2 years ago)

EP1129088A2 TAKEDA PHARMS USA Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole
Jun, 2020

(2 years ago)

EP1129088B1 TAKEDA PHARMS USA Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole
Jun, 2020

(2 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal Jul, 2023

(9 months from now)

US8722084 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 10 days from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 10 days from now)

US8722084

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form Jul, 2026

(3 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation Aug, 2026

(3 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount Sep, 2026

(3 years from now)

US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Feb, 2027

(4 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount Mar, 2027

(4 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules Jan, 2028

(5 years from now)

US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food Mar, 2030

(7 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food Sep, 2030

(7 years from now)

US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy Mar, 2032

(9 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd); to maintain healing of ee and relief of heartburn; for healing of all grades of erosive esophagitis (ee); Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; healing of all grades of erosive esophagitis (ee) for up to 8 weeks; maintain healing of erosive esophagitis (ee) for up to 6 months; Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

6. Drug name - DEXILANT SOLUTAB

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6664276 TAKEDA PHARMS USA Benzimidazole compound crystal
Jan, 2023

(3 months from now)

CN1150186C TAKEDA PHARMS USA Benzimidazole Compound Crystal
Jun, 2020

(2 years ago)

CN1355798A TAKEDA PHARMS USA Benzimidazole Compound Crystal
Jun, 2020

(2 years ago)

EP1977751A1 TAKEDA PHARMS USA Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent
Jun, 2020

(2 years ago)

EP1977751B1 TAKEDA PHARMS USA Amorphous (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole As Anti-Ulcer Agent
Jun, 2020

(2 years ago)

EP1129088A2 TAKEDA PHARMS USA Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole
Jun, 2020

(2 years ago)

EP1129088B1 TAKEDA PHARMS USA Crystalline Form Of (R)-2-[[[3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinyl]Methyl]Sulfinyl]-1H-Benzimidazole
Jun, 2020

(2 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6664276

(Pediatric)

TAKEDA PHARMS USA Benzimidazole compound crystal Jul, 2023

(9 months from now)

US8784885 TAKEDA PHARMS USA Controlled release preparation Oct, 2023

(1 year, 10 days from now)

US8784885

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Apr, 2024

(1 year, 6 months from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form Jan, 2026

(3 years from now)

US9011926 TAKEDA PHARMS USA Method for producing granules Feb, 2026

(3 years from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form Jul, 2026

(3 years from now)

US8871273 TAKEDA PHARMS USA Method for producing granules Jan, 2028

(5 years from now)

US8871273

(Pediatric)

TAKEDA PHARMS USA Method for producing granules Jul, 2028

(5 years from now)

US9241910 TAKEDA PHARMS USA Orally-disintegrating solid preparation Mar, 2029

(6 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL Discontinued

7. Drug name - DUETACT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700128 TAKEDA PHARMS USA Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester Jan, 2027

(4 years from now)

US8071130 TAKEDA PHARMS USA Solid preparation Jun, 2028

(5 years from now)

More Information on Dosage
Strength Dosage Availability
2MG;30MG TABLET;ORAL Prescription
4MG;30MG TABLET;ORAL Prescription

8. Drug name - EXKIVITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

CN106559991B TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

CN106559991A TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3409669B1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916B1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916A4 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3409669A1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916A1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription

9. Drug name - FOSRENOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7381428 TAKEDA PHARMS USA Stabilized lanthanum carbonate compositions Aug, 2024

(1 year, 10 months from now)

US7465465 TAKEDA PHARMS USA Pharmaceutical formulation comprising lanthanum compounds Aug, 2024

(1 year, 10 months from now)

US8980327 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds Dec, 2030

(8 years from now)

US9023397 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds Dec, 2030

(8 years from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Treatment: Reduction of serum phosphate in patients with end stage renal disease

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1GM BASE TABLET, CHEWABLE;ORAL Prescription
EQ 250MG BASE TABLET, CHEWABLE;ORAL Discontinued
EQ 500MG BASE TABLET, CHEWABLE;ORAL Prescription
EQ 750MG BASE TABLET, CHEWABLE;ORAL Prescription

10. Drug name - ICLUSIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114874 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Jan, 2027

(4 years from now)

US9493470 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-B] pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

US11192897 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt
Dec, 2033

(11 years from now)

CN103435595A TAKEDA PHARMS USA Acetylenic Heteroaryl Compounds
Jun, 2015

(7 years ago)

CN101489558A TAKEDA PHARMS USA Acetylenic Heteroaryl Compounds
Aug, 2015

(7 years ago)

CN103467385A TAKEDA PHARMS USA Single-Ring Heteroaryl Compounds
Apr, 2021

(1 year, 5 months ago)

CN101490053A TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Apr, 2021

(1 year, 5 months ago)

CN101490053B TAKEDA PHARMS USA Single-Ring Heteroaryl Compounds
Apr, 2021

(1 year, 5 months ago)

CN103467385B TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
Apr, 2021

(1 year, 5 months ago)

CN101389338B TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

CN103044432A TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

CN101389338A TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

CN103044432B TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

IN200802328P2 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

IN267087B TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP3417912A1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP2495016B1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP3417912B1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP2495016A1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Dec, 2026

(4 years from now)

EP2024366A2 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

EP2024366A4 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

EP2024366B1 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

EP1973545A2 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Jul, 2028

(5 years from now)

EP1973545A4 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Jul, 2028

(5 years from now)

EP1973545B1 TAKEDA PHARMS USA Bicyclic Heteroaryl Compounds
Jul, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9029533 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors Dec, 2026

(4 years from now)

US11192895 TAKEDA PHARMS USA Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt Dec, 2033

(11 years from now)

Drugs and Companies using PONATINIB HYDROCHLORIDE ingredient

Treatment: A method of treating chronic myelogenous leukemia; a method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for the treatment of leukemias; a method for treating acute lymphoblastic leukemia; A method for treating philadelphia chromosome positive acute lymphoblastic leukemia; a method for treating leukemia resulting from a mutation in the bcr-abl kinase domain; a method for treating chronic myeloid leukemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 45MG BASE TABLET;ORAL Prescription

11. Drug name - INTUNIV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6811794

(Pediatric)

TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles Jan, 2023

(2 months from now)

Drugs and Companies using GUANFACINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 2MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 3MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 4MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

12. Drug name - KAZANO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

CN1926128A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2011

(11 years ago)

CN102127057A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2013

(9 years ago)

CN102140090A TAKEDA PHARMS USA Dipeptidyl-Peptidase Inhibitor
Dec, 2013

(8 years ago)

CN102134230B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134230A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134231A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102134229B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134229A TAKEDA PHARMS USA Dipeptide Group Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102079743B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102079743A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102134231B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

IN244233B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhbitors
Dec, 2024

(2 years from now)

EP1586571B1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571A1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571B3 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors Mar, 2025

(2 years from now)

US8900638 TAKEDA PHARMS USA Solid preparation comprising alogliptin and metformin hydrochloride May, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;1GM TABLET;ORAL Prescription
EQ 12.5MG BASE;500MG TABLET;ORAL Prescription

13. Drug name - MYDAYIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6913768 TAKEDA PHARMS USA Sustained release delivery of amphetamine salts May, 2023

(7 months from now)

US9173857 TAKEDA PHARMS USA Controlled dose drug delivery system May, 2026

(3 years from now)

US8846100 TAKEDA PHARMS USA Controlled dose drug delivery system Aug, 2029

(6 years from now)

Drugs and Companies using AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE ingredient

Treatment: Treatment of attention deficit hyperactivity disorder

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
3.125MG;3.125MG;3.125MG;3.125MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
6.25MG;6.25MG;6.25MG;6.25MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
9.375MG;9.375MG;9.375MG;9.375MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
12.5MG;12.5MG;12.5MG;12.5MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

14. Drug name - NESINA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

CN1926128A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2011

(11 years ago)

CN102127057A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2013

(9 years ago)

CN102140090A TAKEDA PHARMS USA Dipeptidyl-Peptidase Inhibitor
Dec, 2013

(8 years ago)

CN102134230B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134230A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134231A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102134229B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134229A TAKEDA PHARMS USA Dipeptide Group Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102079743B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102079743A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102134231B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

IN244233B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhbitors
Dec, 2024

(2 years from now)

EP1586571B1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571A1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571B3 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors Dec, 2025

(3 years from now)

US8697125 TAKEDA PHARMS USA Tablet preparation without causing a tableting trouble Jun, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 6.25MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

15. Drug name - NINLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546608 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same
Aug, 2024

(1 year, 10 months from now)

US8530694 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8003819 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US7687662 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8859504 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof
Jun, 2029

(6 years from now)

US7442830 TAKEDA PHARMS USA Proteasome inhibitors
Nov, 2029

(7 years from now)

CN102066386A TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Apr, 2014

(8 years ago)

CN103497232A TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jan, 2016

(6 years ago)

CN103497210A TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Dec, 2017

(4 years ago)

CN103435638A TAKEDA PHARMS USA Ester Compound And Pharmaceutical Compositions Thereof
Feb, 2018

(4 years ago)

CN103450241A TAKEDA PHARMS USA Borate Ester Compound And Pharmaceutical Compositions Thereof
Mar, 2018

(4 years ago)

CN103467565A TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Sep, 2018

(4 years ago)

CN1867572B TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Use Thereof
Aug, 2024

(1 year, 10 months from now)

CN1867572A TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Use Thereof
Aug, 2024

(1 year, 10 months from now)

CN101772507B TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN102961387B TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN105837608A TAKEDA PHARMS USA Proteasome Inhibitor And Composition And Application Thereof
Aug, 2027

(4 years from now)

CN105837608B TAKEDA PHARMS USA Proteasome Inhibitors And Compositions And Uses Thereof
Aug, 2027

(4 years from now)

CN102961387A TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN101772507A TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

IN231455B TAKEDA PHARMS USA Boronic Acid And Ester Compounds, Pharmaceutical Compounds Comprising Them And Process For Their Preparation .
Aug, 2024

(1 year, 10 months from now)

IN200600565P2 TAKEDA PHARMS USA Boronic Acid And Ester Compounds, Pharmaceutical Compounds Comprising Them And Process For Their Preparation
Aug, 2024

(1 year, 10 months from now)

IN290327B TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

IN201100107P1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

IN201000939P1 TAKEDA PHARMS USA Proteasome Inhibitors
Feb, 2030

(7 years from now)

IN295244B TAKEDA PHARMS USA Proteasome Inhibitors
Feb, 2030

(7 years from now)

EP2730581B1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jul, 2017

(5 years ago)

EP2730581A1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jul, 2017

(5 years ago)

EP1660507B1 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507A2 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507B2 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP1660507B9 TAKEDA PHARMS USA Proteasome Inhibitors And Methods Of Using The Same
Aug, 2024

(1 year, 10 months from now)

EP2178888B1 TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

EP2178888A1 TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

EP2318419B1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

EP2318419A1 TAKEDA PHARMS USA Boronate Ester Compounds And Pharmaceutical Compositions Thereof
Jun, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233115 TAKEDA PHARMS USA Proteasome inhibitors and methods of using the same Aug, 2024

(1 year, 10 months from now)

US8871745 TAKEDA PHARMS USA Proteasome inhibitors Aug, 2027

(4 years from now)

US9175017 TAKEDA PHARMS USA Boronate ester compounds and pharmaceutical compositions thereof Jun, 2029

(6 years from now)

Drugs and Companies using IXAZOMIB CITRATE ingredient

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.3MG BASE CAPSULE;ORAL Prescription
EQ 3MG BASE CAPSULE;ORAL Prescription
EQ 4MG BASE CAPSULE;ORAL Prescription

16. Drug name - OMONTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7528104 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

US7414105 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

US7919118 TAKEDA PHARMS USA Spacer moiety for poly (ethylene glycol) modified peptide based compounds
May, 2024

(1 year, 7 months from now)

US7084245 TAKEDA PHARMS USA Peptides that bind to the erythropoietin receptor
May, 2024

(1 year, 7 months from now)

CN1823088B TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
Jul, 2015

(7 years ago)

CN1823088A TAKEDA PHARMS USA Generating New Peptide Receptor Binding
Jul, 2015

(7 years ago)

CN1823087A TAKEDA PHARMS USA Generating New Peptide Receptor Binding
Apr, 2019

(3 years ago)

CN100441595C TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
Apr, 2019

(3 years ago)

IN200502499P2 TAKEDA PHARMS USA A Peptide Dimer
May, 2024

(1 year, 7 months from now)

IN224732B TAKEDA PHARMS USA A Peptide Dimer
May, 2024

(1 year, 7 months from now)

IN200502493P2 TAKEDA PHARMS USA A Peptide Cross-Reference To Related Applications
May, 2024

(1 year, 7 months from now)

IN228387B TAKEDA PHARMS USA A Peptide
May, 2024

(1 year, 7 months from now)

EP1629007B1 TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1625156A2 TAKEDA PHARMS USA Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1625156B1 TAKEDA PHARMS USA Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

EP1629007A2 TAKEDA PHARMS USA Novel Peptides That Bind To The Erythropoietin Receptor
May, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919461 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses Jun, 2026

(3 years from now)

US7550433 TAKEDA PHARMS USA Erythropoietin receptor peptide formulations and uses Jun, 2026

(3 years from now)

Drugs and Companies using PEGINESATIDE ACETATE ingredient

Treatment: Treatment of anemia due to chronic kidney disease

Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued
EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) SOLUTION;INTRAVENOUS, SUBCUTANEOUS Discontinued

17. Drug name - OSENI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

CN1926128A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2011

(11 years ago)

CN102127057A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2013

(9 years ago)

CN102140090A TAKEDA PHARMS USA Dipeptidyl-Peptidase Inhibitor
Dec, 2013

(8 years ago)

CN102134230B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134230A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134231A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102134229B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102134229A TAKEDA PHARMS USA Dipeptide Group Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102079743B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

CN102079743A TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitor
Dec, 2024

(2 years from now)

CN102134231B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Dec, 2024

(2 years from now)

IN244233B TAKEDA PHARMS USA Dipeptidyl Peptidase Inhbitors
Dec, 2024

(2 years from now)

EP1586571B1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571A1 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

EP1586571B3 TAKEDA PHARMS USA Dipeptidyl Peptidase Inhibitors
Sep, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors Mar, 2025

(2 years from now)

US8637079 TAKEDA PHARMS USA Solid preparation comprising alogliptin and pioglitazone Jun, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 45MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 45MG BASE TABLET;ORAL Prescription

18. Drug name - TRINTELLIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7144884 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Jun, 2026

(3 years from now)

US8722684 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2031

(8 years from now)

CN101636161A TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulphanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition
Apr, 2015

(7 years ago)

CN1561336A TAKEDA PHARMS USA Phenylpiperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

CN1319958C TAKEDA PHARMS USA Phenylpiperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

CN101472906B TAKEDA PHARMS USA Combination For Medicament For Treating Cognitive Impairment The Combination Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A Activity Of 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine
Jun, 2027

(4 years from now)

CN102617513A TAKEDA PHARMS USA 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine Of Compound As A Medicament For Treating Cognitive Impairment, Comprising Combined Activity Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A
Jun, 2027

(4 years from now)

CN102617513B TAKEDA PHARMS USA As A Medicament For Treating Cognitive Impairment, A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity Of 1 - (2 - (2, 4 - - Dimethyl Phenyl Sulfur Alkyl) - Phenyl] Piperazine
Jun, 2027

(4 years from now)

CN102614179A TAKEDA PHARMS USA Combination For Medicament For Treating Cognitive Impairment The Combination Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A Activity Of 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine
Jun, 2027

(4 years from now)

CN101472906A TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

CN102614179B TAKEDA PHARMS USA As A Medicament For Treating Cognitive Impairment, A Compound Having Serotonin Reuptake Activity Of Binding, 5-Ht3 And 5-Ht1A Of 1 - [2 - (2, 4-Dimethyl Phenyl Sulfanyl) - Phenyl] Piperazine
Jun, 2027

(4 years from now)

IN257628B TAKEDA PHARMS USA Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

IN227963B TAKEDA PHARMS USA Pharmaceutical Composition Comprising Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

IN200800326P4 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

IN200400910P4 TAKEDA PHARMS USA Pharmaceutical Composition Comprising Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

IN200806886P4 TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake,5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

IN322445B TAKEDA PHARMS USA A Process For The Preparation Of 1-[2- (2,4- Dimethylphenylsulfa Nyl)Phenyl] Piperazine
Jun, 2027

(4 years from now)

EP1749818A3 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

EP1749818B1 TAKEDA PHARMS USA Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

EP1749818A2 TAKEDA PHARMS USA Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(2 days ago)

EP2044043A1 TAKEDA PHARMS USA 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

EP2439201B1 TAKEDA PHARMS USA Compounds With Combined Sert, 5-Ht3 And 5-Ht1A Activity
Jun, 2027

(4 years from now)

EP2044043B2 TAKEDA PHARMS USA 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine Hydrobromide As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

EP2044043B1 TAKEDA PHARMS USA 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine Hydrobromide As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

EP2439201A1 TAKEDA PHARMS USA Compounds With Combined Sert, 5-Ht3 And 5-Ht1A Activity
Jun, 2027

(4 years from now)

EP1436271B3 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2027

(4 years from now)

EP1436271A1 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2027

(4 years from now)

EP1436271B1 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2027

(4 years from now)

EP2142193B1 TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition
Mar, 2028

(5 years from now)

EP2142193A2 TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition
Mar, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9125909 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US8969355 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9125908 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9227946 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9861630 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9125910 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity Mar, 2032

(9 years from now)

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Treatment: Use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function; Method of treating depression or major depressive disorder; Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Discontinued
EQ 20MG BASE TABLET;ORAL Prescription

19. Drug name - ULORIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361676 TAKEDA PHARMS USA Solid preparation containing single crystal form Mar, 2024

(1 year, 5 months from now)

US8372872 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat Sep, 2031

(8 years from now)

US9107912 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat Sep, 2031

(8 years from now)

Drugs and Companies using FEBUXOSTAT ingredient

Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription

20. Drug name - VELCADE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6713446 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(8 months ago)

US6958319 TAKEDA PHARMS USA Formulation of boronic acid compounds
Jan, 2022

(8 months ago)

EP2251344A1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP1355910A1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP2251344B1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP1355910B1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP3078667B1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

EP3078667A1 TAKEDA PHARMS USA Formulation Of Boronic Acid Compounds
Jan, 2022

(8 months ago)

Drugs and Companies using BORTEZOMIB ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
3.5MG/VIAL INJECTABLE;INTRAVENOUS, SUBCUTANEOUS Prescription

21. Drug name - VYVANSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7655630 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(4 months from now)

US7662787 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds
Feb, 2023

(4 months from now)

US7659253 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs
Feb, 2023

(4 months from now)

CN1747737A TAKEDA PHARMS USA Saccharide Conjugates Prevent Abuse Of The Control Medicine
Sep, 2011

(11 years ago)

CN101193650A TAKEDA PHARMS USA Abuse-Resistance Amphetamine Prodrugs
Dec, 2012

(9 years ago)

CN1476325A TAKEDA PHARMS USA Conveying System And Method Of Protecting And Administering Active Material Active Material
Oct, 2015

(6 years ago)

CN1476325B TAKEDA PHARMS USA Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents
Oct, 2015

(6 years ago)

CN100413533C TAKEDA PHARMS USA A Pharmaceutical Compound For Preventing Sustained Release Of Control Of Substance Abuse
Feb, 2022

(7 months ago)

CN1720059A TAKEDA PHARMS USA Sustained Release Model Of Preventing Substance Abuse Of A Pharmaceutical Compound
Feb, 2022

(7 months ago)

CN1816346A TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

CN1816346B TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

CN1925865B TAKEDA PHARMS USA Pharmaceutical Composition Of Preventing Overdose Or Abuse
Sep, 2024

(1 year, 11 months from now)

CN1925865A TAKEDA PHARMS USA Pharmaceutical Compositions For Prevention Of Overdose Or Abuse
Sep, 2024

(1 year, 11 months from now)

IN200401300P2 TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

IN231459B TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

IN250464B TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

IN200502683P2 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds Cross Reference Related Applications
Jun, 2024

(1 year, 7 months from now)

EP1311242A4 TAKEDA PHARMS USA Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents
Aug, 2021

(1 year, 1 month ago)

EP1311242B1 TAKEDA PHARMS USA Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents
Aug, 2021

(1 year, 1 month ago)

EP1311242A1 TAKEDA PHARMS USA Active Agent Delivery Systems And Methods For Protecting And Administering Active Agents
Aug, 2021

(1 year, 1 month ago)

EP1401374A1 TAKEDA PHARMS USA A Novel Pharmaceutical Compound Containing Atenolol And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1401374B1 TAKEDA PHARMS USA A Novel Pharmaceutical Compound Containing Atenolol And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1401374A4 TAKEDA PHARMS USA A Novel Pharmaceutical Compound Containing Abacavir Sulfate And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1357928A2 TAKEDA PHARMS USA A Novel Pharmaceutical Compound And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1357928B1 TAKEDA PHARMS USA A Novel Pharmaceutical Compound And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1357928A4 TAKEDA PHARMS USA A Novel Pharmaceutical Compound And Methods Of Making And Using Same
Nov, 2021

(10 months ago)

EP1531844A4 TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

EP1531844A2 TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

EP1531844B1 TAKEDA PHARMS USA Novel Sustained Release Pharmaceutical Compounds To Prevent Abuse Of Controlled Substances
Feb, 2023

(4 months from now)

EP1594513B1 TAKEDA PHARMS USA Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances
Jan, 2024

(1 year, 3 months from now)

EP1594513A4 TAKEDA PHARMS USA Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances
Jan, 2024

(1 year, 3 months from now)

EP1594513A2 TAKEDA PHARMS USA Carbohydrate Conjugates To Prevent Abuse Of Controlled Substances
Jan, 2024

(1 year, 3 months from now)

EP1644019A1 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

EP1644019A4 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

EP1644019B1 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

EP1644019B2 TAKEDA PHARMS USA Abuse Resistant Amphetamine Compounds
Jun, 2024

(1 year, 7 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659254 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7678771 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7674774 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7662788 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7105486 TAKEDA PHARMS USA Abuse-resistant amphetamine compounds Feb, 2023

(4 months from now)

US7671031 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7671030 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7687467 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7678770 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7718619 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7223735 TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds Feb, 2023

(4 months from now)

US7687466 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7713936 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7723305 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7700561 TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Feb, 2023

(4 months from now)

US7723305

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7671030

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7223735

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds Aug, 2023

(10 months from now)

US7671031

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7655630

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7662788

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7659253

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7662787

(Pediatric)

TAKEDA PHARMS USA Abuse resistant lysine amphetamine compounds Aug, 2023

(10 months from now)

US7659254

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7105486

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine compounds Aug, 2023

(10 months from now)

US7674774

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7678770

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7687466

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7678771

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7687467

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7713936

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7718619

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

US7700561

(Pediatric)

TAKEDA PHARMS USA Abuse-resistant amphetamine prodrugs Aug, 2023

(10 months from now)

Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd); indicated for the treatment of attention-deficit/hyperactivity disorder (adhd)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG CAPSULE;ORAL Prescription
20MG CAPSULE;ORAL Prescription
30MG CAPSULE;ORAL Prescription
40MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription
60MG CAPSULE;ORAL Prescription
70MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.